KKR completed its acquisition of Integer Holdings for $5.7 billion, taking the medical device contract manufacturer private and removing a mid-cap supplier from public markets. The deal closed at $127 per share, a 42% premium to Integer's six-month average before announcement. Integer generated $1.6 billion in trailing revenue across cardiac rhythm management, neuromodulation, and portable medical components.
Integer operates as a Tier 2 supplier — it builds batteries, enclosures, and subassemblies for Medtronic, Abbott, and Boston Scientific, but does not own end-product IP or brand relationships. The company holds 19% operating margins, rare for contract manufacturing, because switching costs in FDA-regulated components are extreme. KKR inherits $680 million in net debt and a customer base that cannot easily re-qualify alternate suppliers without multi-year validation cycles. The acquisition removes quarterly earnings pressure on a business where R&D payback horizons stretch five to seven years.
This is KKR's third medical device platform investment since 2021, following its $2.9 billion acquisition of Envision Healthcare's ambulatory surgery assets and a minority stake in Aesculap Implant Systems. The firm is building vertical exposure across the device stack — components, contract manufacturing, and ambulatory distribution. Integer's $340 million EBITDA gives KKR immediate cash generation to fund bolt-on acquisitions of smaller device component suppliers, particularly in Europe where fragmentation is higher. The take-private also insulates Integer from public-market volatility around Medicare reimbursement policy, which has compressed device manufacturer multiples by 18% since September.
Allocators should watch for KKR's next moves in the neuromodulation component segment, where Integer holds 34% North American market share. The firm now controls a chokepoint in spinal cord stimulator and deep brain stimulator supply chains. Expect bolt-on acquisitions of smaller battery and lead-wire manufacturers in Germany and Switzerland within twelve to eighteen months. Also monitor whether KKR pushes Integer to in-license component IP from university medical centers — a strategy that would shift the company from pure manufacturing toward higher-margin design services.
The Integer deal closes the same quarter that Altaris Capital took Paragon 28 private for $1.1 billion and Permira acquired a majority stake in Avent Medical. Mid-tier device companies are disappearing from public markets because growth investors no longer tolerate the 8-12 quarter FDA clearance cycles that define the sector. Private equity is now the only buyer willing to hold through multi-year product validation timelines.